Draeger unveils new non-invasive jaundice meter for infants in UK

12 November 2013 (Last Updated November 12th, 2013 18:30)

Germany-based Draeger is to launch its JM-105 jaundice meter in the UK; it is a new device for non-invasive transcutaneous bilirubinometer designed to identify at-risk infants as young as the 24 weeks gestational age.

jm 150

Germany-based Draeger is to launch its JM-105 jaundice meter in the UK; it is a new device for non-invasive transcutaneous bilirubinometer designed to identify at-risk infants as young as the 24 weeks gestational age.

The Draeger Jaundice meter JM-105 will be unveiled at the Annual Conference for the Royal College of Midwives.

While the readings are taken by gently pressing the sensor on the infants' forehead or sternum, all device functions can be controlled using a colour touchscreen.

The sensor can be easily cleaned by rubbing alcohol before every screening process and as the device is reusable, eliminating the need for disposable products.

According to NHS statistics, six out of ten babies born in the UK will develop jaundice, but it may rise to eight out of ten for babies born prematurely.

A study of premature infants from the 24th week showed that repeated pain experiences can affect the maturation of neuronal structures, which may adversely affect brain and emotional development.

The JM-105 streamlines jaundice screening practices by reducing or even eliminating painful, repeated blood-draws particularly in young patients.

This new, non-invasive meter provides multiple advantages compared to currently used methods for diagnosing jaundice in infants.

It can identify newborns at an increased risk for hyperbilirubinemia with high accuracy.

The device configuration setting can also be adjusted to just take a single measurement or up to five measurements for an average value.

According to the company, till date, jaundice screening as early as the 24th week gestational age was not yet approved for use in many countries.

"Patient data and user information can be captured via barcode scanner or manually inputted. It is then electronically transferred to ensure patient record accuracy and without the need to wait for blood tests or possible hospital readmission."

The JM-105 contributes to reducing painful examinations for these patients, thereby supporting their development.

Draeger neonatal care sales and marketing manager Luke Bourdillon said the JM-105 allows for non-invasive testing and means the number of painful examinations on these tiny patients can be reduced, helping support their development.

"As well as the obvious patient benefits, the JM-105 offers great benefits to care givers," Bourdillon said.

"Patient data and user information can be captured via barcode scanner or manually inputted. It is then electronically transferred to ensure patient record accuracy and without the need to wait for blood tests or possible hospital readmission."

JM-105 can store up to 100 measurement results and transmit them via a docking station to the clinic's patient data management system.

The new meter transfers all readings and data stored in the device electronically via the interface standard HL 7.

A nurse can identify abnormal values by attaching a flag symbol to a patient's measurement. Enabling the clinical team to later locate the patient more quickly for further assessment.

Draeger believes the JM-105 can help caregivers non-invasively measure bilirubin levels in newborns as young as 24 weeks gestational age thereby, eliminating possible long-term consequences in very young patients.


Image: Non-invasive jaundice screening with the Draeger JM-105. Photo: courtesy of Drägerwerk AG & Co KGaA.